dramatically, such that an individual suffering from metastatic PC may lose approximately 9 to 10 years of life expectancy (2) . More than 90% of PCs are diagnosed between 45 and 89 years of age (average, 72 years of age). Because the risk of PC bears a strong relationship to age, the incidence [1 in 10,000 at <39 years of age to 1 in 6 for men > 80 years of age (1) ] can be expected to rise because men are living longer than ever before (3) . Other risk factors include family history (4), higher intake of dietary fat (5, 6) , high blood levels of male sex hormones, and Americans of African origin. Vitamins D and E and selenium are suggested to have a protective effect (7, 8) , whereas the role of vitamin A is controversial.
Pathology of Prostate Cancer
Histopathologically, high-grade prostatic intraepithelial neoplasia (HGPIN) is considered the most likely precursor of invasive PC because of its peripheral zone location and immunohistochemical expression of biomarkers similar to that of PC (9) . Prostatic intraepithelial neoplasia is present in 85% of PC samples (10) . Histologically, almost all PCs are adenocarcinomas originating from the prostatic glandular epithelium. The most widely used system of grading PC is the Gleason system (11, 12) , which takes into account the degree of glandular differentiation of epithelial cells in relation to stroma at relatively low magnification. Grades range from 1 to 5 depending on tumor architecture, which varies from well differentiated (showing a preserved glandular pattern) to poorly differentiated ( showing no definite glandular architecture). A combined Gleason's score or Gleason's sum (2-10) is determined by adding the most frequent primary and secondary pattern of cellular architecture in a heterogeneous tumor.
PC spreads to local as well as distant sites. Local spread can involve adjacent viscera including seminal vesicles, ejaculatory ducts, and rectum. The most frequent sites of metastatic spread are lymph nodes, bones, and lungs. Less common sites include bladder, liver, and adrenal glands (13) .
Because of the gravity of extraprostatic disease, a screening program designed to detect PC at a curable stage appears logical. However, there are limitations with present screening methods; even after histologic diagnosis has been made, the biologic behavior of individual PC cannot be predicted. Identification of those cases of localized PC that require definitive treatment from those in which no treatment is the appropriate option remains an issue.
At present no definite biologic or molecular marker exists that can predict the future clinical behavior of PC while it is still localized to the prostate [reviewed by Isaacs (14) and Lalani et al. (15) (18) . This is in sharp contrast to clinically important cancer, which is rare in Asia (1:100,000) but reaches epidemic proportions in the West; the highest rates reported are in Americans ofAfrican origin (19) .
For the clinician the challenge is to distinguish between patients with localized disease (T1,2NoM0) that is a) dinically significant and that will metastasize if untreated, usually justifying radical therapy; b) dinically significant but is an apparently localized disease with unidentifiable occult metastases using current imaging techniques in whom there is no curative option (but these patients may be subjected to radical therapy in the hope of cure); and c) latent cancer that will not affect them during their lifetime. There are currently no clinical or molecular tests to distinguish between these three groups ofpatients. (65) (66) (67) (68) (69) , and in transport of proteins across cellular membranes e.g., across the nuclear membrane (68, 70, 71) . Recently it has been proposed that Bcl-2 regulates activation of caspase proteases (72-79), which are responsible for the final executionary steps of apoptosis ( Figure 3A, B) . There is as yet no evidence that these functions are a result of the direct action of Bcl-2. These may, however, be consequences of Bcl-2 action upstream of these events. In the last 2 years, Bcl-2 function has been extensively studied in relation to its regulation of permeability transition (PT) in mitochondria. The induction of PT can result in loss of membrane potential (80, 81) , inhibition of oxidative phosphorylation, generation of reactive oxygen species, and release of proteins such as cytochrome c. Cytochrome c normally resides in the intermembrane space of the mitochondria and on its translocation to cytosol can induce activation of caspases (81, 82) (Figure 3A, B the mitochondrial space and stabilizes the mitochondrial potential (AT) in response to apoptosis-inducing agents, for example, stauroporine (83) . Furthermore, a proposed pore-forming capability of Bcl-2, BCI-XL, and Bax in lipid membranes (84-87), similar to those of the bacterial toxins (e.g., diphtheria) and colicins suggests a novel function for these proteins as channels for ions, proteins, or both.
Bcl-2 Family Proteins Determinants of Chemosensitivity
The survival advantage provided by Bcl-2 contributes not only to the development of cancer but also to resistance against a wide variety of anticancer agents including cyclophosphamide, cisplatin, etoposide (VP16), mitoxantrone, adriamycin, cytosine arabinoside, methotrexate, 5-fluorouracil, thapsigargin, stauroporine, dexamethasone, and radiation (68, (88) (89) (90) (91) (92) (93) (94) (95) . Bcl-XL, a death antagonist, also suppresses the apoptotic effect of a number of cytotoxic agents (77, 94) . Inhibition of apoptosis induced by a variety of anticancer agents by Bcl-2 and BCl-XL suggests a common potential pathway (38, 77, 94, 96) . Downregulation of Bcl-2 protein can lead to a reversal of chemoresistance, rendering cancer cells sensitive to the cytotoxic effects of conventional cytotoxic chemotherapy (97) (98) (99) (100) . In contrast, upregulation of proapoptotic Bcl-2 members, such as Bax, Bcl-Xs, and Bak, can induce chemosensitization (101) (102) (103) .
The function of Bcl-2 is unique because it does not affect the pharmacokinetics of the anticancer drugs. It blocks the transmission of signals originating from the damage to the effectors of apoptosis, allowing cells to survive in the presence of otherwise lethal damage, enhancing the chances of acquiring genetic alterations and favoring the development of a more malignant phenotype.
Role of Apoptos in the Development and Progression of Prostate Cancer
Normal prostatic glandular cells have a low proliferation rate (< 0.3%/day) that is efficiently balanced by the same rate of apoptosis so that there is no net growth (104) . During Bcd-2 GENE FAMILY PROTEINS AND PROSTATE CANCER indicate that there is a decrease in cell death (and no further increase in proliferation rate as compared to HGPIN) that is responsible for its continuous growth (104) . A similar situation occurs in metastatic PCs in which the proliferation rate is also low (< 3%) (104) . These cell kinetic data provide an explanation as to why conventional cytotoxic chemotherapy (which usually targets actively proliferating cancer cells) fails to kill PC cells and suggests that proliferation-independent therapeutic strategies may be more beneficial for the treatment of PC.
Androgen ablative therapies are the mainstay of treatment in extraprostatic PC. Androgen ablation has a dual effect i.e., inhibiting epithelial cellular proliferation and promoting apoptosis (105 (32, 34) . This means that in Al PC, resistance to apoptotic-inducing cytotoxic chemotherapeutics is contributed both by slow proliferation and acquisition of the antiapoptotic potential owing to the dysregulated expression of antiapoptotic Bcl-2 homologs. Therefore, potential measures to overcome cytotoxic chemoresistance in AI PC can be achieved either by introducing proliferation-independent treatment strategies and/or restoring sensitivity to induce apoptosis in cancer cells. Thapsigargin, for example, could induce apoptotic cell death independent of cell proliferation (107, 108) . Thapsigargin is a specific inhibitor of endoplasmic reticulum (ER) Ca-ATPase and results in the depletion of the ER pool and the subsequent signaling of a sustained influx of extracellular calcium (109) . Agents that could target Bcl-2 or related antiapoptotic proteins and therefore sensitize cancer cells to undergo apoptosis could also be useful as new therapeutic modalities in the management of PC.
Bcl-2 and Prostate Cancer Progression
De novo expression of BcI-2 has been reported in a number of epithelial malignancies including those arising from the breast, urinary bladder, thyroid, stomach, lung, intestine, and prostate (32, 34, (110) (111) (112) (113) (114) (115) (116) (117) (118) (119) (120) (121) (122) (123) (124) (125) (126) (127) (118) . These studies suggest a role for these antiapoptotic proteins in the progression of PC toward AI.
In vitro studies on PC cell lines suggest a role for Bcl-2 in the inhibition of apoptosis and progression to AI (33). Raffo et al. (33) have shown that Bcl-2 transfection into LNCaP cells (a human androgen-sensitive PC cell line) resulted in the inhibition of apoptosis in response to serum (growth factors) withdrawal in contrast to apoptotic cell death in controls. Moreover, Bcl-2 expression provided a growth advantage in the absence of androgens i.e., LNCaPlBcl-2 transfectant xenografts in nude mice continued their growth after castration, whereas tumors formed by the control transfectant regressed after castration and showed evidence of apoptotic cell death (33 The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. Cell Growth Differ 5:411-417
